Clinical Trial Update: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of cilta-cel (ciltacabtagene autoleucel) and talquetamab in high-risk multiple myeloma. The study status is active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Abecma (idecabtagene vicleucel)
• Talquetamab (talquetamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING